Avanos Medical Company Insiders
AVNS Stock | USD 19.03 0.57 2.91% |
Avanos Medical employs about 3.8 K people. The company is managed by 25 executives with a total tenure of roughly 106 years, averaging almost 4.0 years of service per executive, having 150.84 employees per reported executive. Breaking down Avanos Medical's management performance can provide insight into the firm performance.
Joseph Woody CEO Chief Executive Officer, Director |
Gary Blackford Chairman Independent Non-Executive Chairman of the Board |
Avanos Medical's Insider Buying Vs Selling
50
Selling | Buying |
Latest Trades
2024-03-14 | Michael Greiner | Disposed 8000 @ 19.12 | View | ||
2024-03-11 | Julie Ann Shimer | Acquired 500 @ 19.85 | View |
Monitoring Avanos Medical's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Avanos |
Avanos Medical's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Avanos Medical's future performance. Based on our forecasts, it is anticipated that Avanos will maintain a workforce of slightly above 12000 employees by January 2025.Avanos Medical Management Team Effectiveness
The company has return on total asset (ROA) of 0.0208 % which means that it generated a profit of $0.0208 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0177 %, meaning that it created $0.0177 on every $100 dollars invested by stockholders. Avanos Medical's management efficiency ratios could be used to measure how well Avanos Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.09). At this time, Avanos Medical's Total Current Assets are comparatively stable compared to the past year. Intangibles To Total Assets is likely to gain to 0.63 in 2024, whereas Net Tangible Assets are likely to drop slightly above 181.9 M in 2024.Common Stock Shares Outstanding is likely to gain to about 51.7 M in 2024. Net Income Applicable To Common Shares is likely to gain to about 47.7 M in 2024
Avanos Medical Workforce Comparison
Avanos Medical is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 101,371. Avanos Medical holds roughly 3,771 in number of employees claiming about 4% of equities under Health Care industry.
Avanos Medical Profit Margins
The company has Profit Margin (PM) of 0.02 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.1 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.1.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.37 | 0.5639 |
|
|
Avanos Medical Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avanos Medical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avanos Medical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Avanos Medical insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-09-01 | 0.3333 | 1 | 3 | 3,001 | 684.00 |
2024-03-01 | 0.6087 | 14 | 23 | 328,676 | 91,602 |
2023-03-01 | 1.4444 | 13 | 9 | 254,415 | 24,283 |
2020-06-01 | 5.0 | 15 | 3 | 418,621 | 2,982 |
2019-06-01 | 2.75 | 11 | 4 | 193,072 | 4,265 |
2019-03-01 | 2.5 | 10 | 4 | 57,293 | 9,077 |
2018-06-01 | 5.25 | 21 | 4 | 435,198 | 7,592 |
2017-12-01 | 0.4 | 2 | 5 | 2,811 | 11,327 |
2017-06-01 | 1.375 | 11 | 8 | 459,040 | 29,164 |
2016-06-01 | 0.75 | 9 | 12 | 325,952 | 13,476 |
2015-06-01 | 2.0 | 26 | 13 | 225,749 | 5,914 |
Avanos Medical Notable Stakeholders
An Avanos Medical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Avanos Medical often face trade-offs trying to please all of them. Avanos Medical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Avanos Medical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael CPA | Senior CEO | Profile | |
Joseph Woody | Chief Executive Officer, Director | Profile | |
Gary Blackford | Independent Non-Executive Chairman of the Board | Profile | |
William Haydon | Senior Vice President and General Manager, Pain Management | Profile | |
David Ball | Senior Vice President - Global Supply Chain and Procurement | Profile | |
Michael Greiner | Chief Financial Officer, Senior Vice President | Profile | |
Arjun Sarker | Senior Vice President - International | Profile | |
Patrick OLeary | Independent Director | Profile | |
Julie Shimer | Independent Director | Profile | |
William Hawkins | Independent Director | Profile | |
Heidi Kunz | Independent Director | Profile | |
John Byrnes | Independent Director | Profile | |
Maria Sainz | Independent Director | Profile | |
John Cato | Vice Resources | Profile | |
S Mansbach | Senior Vice President Interim General Counsel, Corporate Secretary | Profile | |
Moji James | Senior Vice President General Counsel | Profile | |
Sigfrido Delgado | Senior Chain | Profile | |
Michelle Scharfenberg | Senior Vice President Chief Ethics and Compliance Officer | Profile | |
Mojirade James | Senior Vice President General Counsel, Corporate Secretary | Profile | |
Lee Burnes | Clinical RD | Profile | |
Scott Galovan | Vice Development | Profile | |
Sudhakar Varshney | Senior Procurement | Profile | |
David Crawford | VP Treasurer | Profile | |
John Hurley | Principal Controller | Profile | |
Kerr Holbrook | Senior Vice President General Manager - Chronic Care | Profile |
About Avanos Medical Management Performance
The success or failure of an entity such as Avanos Medical often depends on how effective the management is. Avanos Medical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Avanos management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Avanos management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.09) | (0.09) | |
Return On Assets | (0.04) | (0.03) | |
Return On Equity | (0.05) | (0.05) |
Please note, the imprecision that can be found in Avanos Medical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Avanos Medical. Check Avanos Medical's Beneish M Score to see the likelihood of Avanos Medical's management manipulating its earnings.
Avanos Medical Workforce Analysis
Traditionally, organizations such as Avanos Medical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Avanos Medical within its industry.Avanos Medical Manpower Efficiency
Return on Avanos Medical Manpower
Revenue Per Employee | 178.5K | |
Revenue Per Executive | 26.9M | |
Net Loss Per Employee | 16.4K | |
Net Loss Per Executive | 2.5M | |
Working Capital Per Employee | 66.9K | |
Working Capital Per Executive | 10.1M |
Additional Tools for Avanos Stock Analysis
When running Avanos Medical's price analysis, check to measure Avanos Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avanos Medical is operating at the current time. Most of Avanos Medical's value examination focuses on studying past and present price action to predict the probability of Avanos Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avanos Medical's price. Additionally, you may evaluate how the addition of Avanos Medical to your portfolios can decrease your overall portfolio volatility.